Company intelligence / Profile preview

Candriam

Ownership: Private
Employees: ~650
Development stage: Other

Overview

Candriam is a global multi-specialist asset management firm recognized for its leadership in sustainable and responsible investing. It manages over $170 billion in assets as of December 2024 and has been investing heavily in healthcare and biotechnology for more than 20 years through dedicated thematic funds such as "Candriam Equities L Biotechnology" and "Global Oncology Equity." The firm leverages deep scientific expertise within its investment teams to select innovative healthcare stocks globally.

Industry: Investors

Partnerships

Strategic partnership with Andera Partners for European private equity market expansion

Beyond the preview

Go deeper on Candriam.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Candriam.

Explore the full profile